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Paraoxonase 1 (PON1)Abstract Introduction: Systemic lupus erythematosus (SLE) patients have an increased risk of
atherosclerosis. Identiﬁcation of at-risk patients and the pathogenesis of atherosclerosis in SLE
remain elusive. Paraoxonase 1 (PON1) and anti-apolipoprotein A-I antibody (anti-Apo A-I) appear
to have a potential role in premature atherosclerosis in SLE.
Aim of the work: To assess two novel risk factors of atherosclerosis in SLE patients; PON1 activ-
ity, and anti-Apo A-I antibody levels, in order to elucidate any possible correlation between both of
them, and to demonstrate their relations to disease activity disease activity as well as disease related
damage.
Patients and methods: Forty SLE female patients and 40 apparently healthy volunteers were
included in this study. Anti-Apo A-I antibody levels and PON1 activity levels were assessed. Sys-
temic Lupus Erythematosus Disease Activity Index (SLEDAI) and Systemic Lupus International
Collaboration Clinics (SLICC)/American College of Rheumatology (ACR) damage index were
preformed to all patients.
208 E.M. Elserougy et al.Results: Compared with controls, SLE patients showed signiﬁcantly lower PON1 activity and
signiﬁcantly higher titers of anti Apo A-I. Anti-Apo A-I antibody titers correlated inversely with
PON1 activity. Elevated titers of anti-Apo A-I antibody and reduced PON1 activity were related
to increased SLEDAI and (SLICC/ACR) damage index scores.
Conclusion: There is a decreased PON1 activity and formation of anti-Apo A-I antibodies in
SLE patients and both of them correlated with disease activity as well as disease-related damage.
PON1 activity and anti-Apo A-I antibodies might be involved in the pathogenesis of premature ath-
erosclerosis in SLE patients.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis.Open access under CC BY-NC-ND license.1. Introduction
Systemic lupus erythematosus (SLE) is a chronic autoim-
mune inﬂammatory disorder that primarily affects women
and can involve virtually any organ in the body [1]. It is
characterized by the presence of autoantibodies against mul-
tiple self antigens and immune complexes that target multi-
ple organ systems [2].
With the increased life expectancy among SLE patients,
accelerated atherosclerosis and subsequent cardiovascular dis-
ease (CVD) have emerged as a signiﬁcant threat that signiﬁ-
cantly contributes to morbidity and mortality [3].
In recent years, there has been a growing interest in under-
standing the pathogenesis of accelerated atherosclerosis in SLE
[4]. Traditional risk factors fail to account fully for the excess
CVD events in SLE patients. Therefore, it has been suggested
that patients possess additional SLE-related risk factors [5].
Epidemiological studies have demonstrated a strong inverse
relationship between high density lipoprotein (HDL) level and risk
for CVD [6]. HDL has a wide range of functions including: reverse
cholesterol transport, antioxidant, anti-inﬂammatory, anti-throm-
botic and anti-atherogenic activity [7]. The protective functions of
HDLcouldbe partly explainedby its constituentsmainly, apolipo-
protein A-I (Apo A-I) and paraoxonase (PON1) [8].
Apo A-I is the major protein component of HDL and is
widely considered to be responsible for the anti-atherogenic
and anti-thrombotic effects of HDL by promoting cellular
cholesterol efﬂux and exerting anti-oxidative and anti-inﬂam-
matory effects [8]. Apo A-I exerts anti-oxidant properties by
stabilizing PON1 [9]. PON1 is an antioxidant enzyme attached
to HDL. PON1 decreases systemic oxidative stress and is asso-
ciated with a lower incidence of CVD [10].
There is an emerging evidence of the presence of anti-Apo
A-I antibodies and the reduction in the plasma levels of
PON1 in SLE patients, thus interfering with the protective
functions of HDL favoring atherogenesis [11].
The aim of the present study was to assess two novel risk
factors of atherosclerosis in SLE patients; PON1 activity,
anti-Apo A-I antibody levels, to ﬁnd any possible correlation
between both of them, and to demonstrate their relations to
disease activity as well as disease related damage.
2. Patients and methods
2.1. Patients
Eighty participants were included in this study; they were
divided into two groups:2.1.2. Group (A): patient group
Forty SLE premenopausal female patients were diagnosed
according to the ACR revised criteria of SLE [12]. Their age
ranged between 18 and 46 years and the SLE disease duration
extended between 0.5 and 15 years. These patients were re-
cruited from Rheumatology and Rehabilitation outpatient
clinic and department of Kasr El-Aini hospitals (Cairo Univer-
sity). SLE patients with parameters known to inﬂuence the
PON1 activity or induce premature atherosclerosis were ex-
cluded namely, smoking, diabetes mellitus, chronic renal failure
or nephrotic syndrome, and antiphospholipid syndrome. Pa-
tients on lipid lowering drugs, known cases of primary dyslipi-
demia and hypothyroidism and family history of CVD were
also excluded.
2.1.3. Group (B): control group
Forty apparently healthy, age – matched female volunteers
served as the control group. Their age ranged between 18
and 47 years.
An informed consent was obtained from all participants in
the study, and the study was approved by the Institutional
Review Board (IRB) of faculty of medicine, Cairo University.
2.2. Methods
All participants were subjected to the following:
1. Comprehensive history taking and thorough clinical examina-
tion; general, cardiopulmonary, abdominal, neurological,
and musculoskeletal system.
2. Routine laboratory investigations (CBC, ESR, liver and kid-
ney functions, and urine analysis, in addition to estimation
of total albumin in 24 h urine), lipid proﬁle (triglycerides
and total serum cholesterol, HDL, and LDL concentra-
tion), immunological assays (ANA, anti-dsDNA antibod-
ies, anticardiolipin antibodies, and lupus anticoagulants),
and serum complement levels (C3 and C4).
3. Determination of anti-Apo A-I antibody levels in the plasma;
96-well plates (PolySorp) were half-coated for 1 h at 37 C
with 10 g/ml human Apo A-I (Sigma–Aldrich) in 70% eth-
anol. Blocking was performed using phosphate buffered
saline containing 1% albumin from bovine serum for 1 h
at 37 C. Hundred microliters of the samples (1:300 dilu-
tions in blocking agent) and positive control were added
to duplicate wells in both halves of the plate and kept for
1 h at 37 C. After washing, alkaline phosphatase-conju-
gated anti-human IgG (1:1000 in the blocking agent) was
added for 1 h. p-Nitrophenyl phosphate (1:5000 in
Table 1 Clinical characteristics of Systemic lupus erythema-
tosus patients (Group A) (n= 40).
Clinical data n (%)
Musculoskeletal manifestation 37 (92.5)
Arthralgia 37 (92.5)
Frank arthritis 28 (70)
Avascular necrosis of bone 6 (15)
Tendinitis 4 (10)
Myositis 3 (7.5)
Deformity 1 (2.5)
Mucocutaneous manifestation 32 (80)
Hair fall 23 (57.5)
Oral ulcer 22 (55)
Skin rash 20 (50)
Photosensitivity 18 (45)
Raynaud’s phenomenon 7 (17.5)
Scarring alopecia 2 (5)
Constitutional manifestation 30 (75)
Fatigue 24 (60)
Fever 21 (52.5)
Weight loss 9 (22.5)
Nephritis 26 (65)
Serositis 16 (40)
Pleurisy 16 (40)
Pericarditis 2 (5)
Central nervous system manifestation 12 (30)
Psychosis 7 (17.5)
Convulsions 6 (15)
Organic brain syndrome 3 (7.5)
Neuropathy and numbness 3 (7.5)
Lupus headache 1 (2.5)
Hepatomegaly 10 (25)
Vasculitis 7 (17.5)
Skin vasculitis 5 (12.5)
Retinal vasculitis 3 (7.5)
Ocular manifestations 7 (17.5)
Retinal vasculitis 3 (7.5)
Episcleritis 1 (2.5)
Secondary Sjo¨gren’s syndrome 4 (10)
Splenomegaly 5 (15)
Lymphadenopathy 3 (7.5)
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37 C for color development and the absorbance read at
405 nm after 1 h. All assays were validated by the inclusion
of internal quality control samples of known activity.
Results were expressed as the percentage of the positive
control present in each plate after subtraction from the
background in the uncoated half of the plate. Inter-/intra-
plate coefﬁcients of variation were <10% [11].
4. Determination of paraoxonase1 activity; serum paraoxonase
1/arylesterase (the activity toward phenyl acetate) was
determined spectrophotometrically at 270 nm with phenyl
acetate used as the substrate. The assay mixture included
1.0 mmol/L of phenyl acetate and 0.9 mmol/L CaCl2 in
20 mmol/L Tris HCl, pH 8.0, at 25 C. Nonenzymatic
hydrolysis of phenyl acetate was subtracted from the
total rate of hydrolysis. The E270 for the reaction is
1310 mol/L1 cm1. The results are expressed in U/ml;
1 U hydrolyzes 1 lmol of phenyl acetate/minute [13].
5. Radiological investigations; chest X-ray, X-ray for any
affected joint.
6. Electrocardiography (ECG); for detection of ischemia, peri-
cardial effusion, pericarditis, and myocarditis.
7. Assessment of disease activity using Systemic Lupus Erythe-
matosus Disease Activity Index (SLEDAI); SLEDAI is a
scale designed speciﬁcally to assess the disease activity in
SLE patients. It measures potentially reversible manifesta-
tions of the underlying inﬂammatory disease process. This
disease activity index covers the symptoms and laboratory
changes at the time of examination as well as in the previous
10 days before examination. It consists of 24 variables cover-
ing nine organ systems (including some serologic tests)
scored according to weights derived using multiple regres-
sion techniques. The ﬁnal score compromises the sum of all
weighted scores. Grading of disease activity to mild (1–10),
moderate (11–20), severe (21–45), and very severe (>45) [14].
8. Assessment of disease related damage was done using Sys-
temic Lupus International Collaborative Clinics/American
College of Rheumatology (SLEICC/ACR) damage index;
the damage in SLE may be due to SLE itself or due to drug
therapy. The index records damage in 12 organs or systems.
The change must have been present for at least 6 months
and is ascertained clinically or by simple investigation [15].
Statistical analysis: Data were statistically described in
terms of mean ± standard deviation (±SD). A comparison
between cases and control groups was done using Student’s t
test for independent samples. Correlation between various
variables was done using Pearson moment correlation equa-
tion for linear relation in normally distributed variables and
Spearman rank correlation equation for non-normal variables.
p Values less than 0.05 were considered statistically signiﬁcant.
All statistical calculations were done using computer programs
SPSS version 15 (Statistical Package for the Social Science;
SPSS Inc., Chicago, IL, USA).
3. Results
Eighty participants were included in this study; they were
divided into two groups; Group (A) included 40 SLE
premenopausal female patients diagnosed according to ACR
revised criteria of SLE. Their age ranged between 18 and46 years with a mean of 28.35 ± 7.06 years. The disease dura-
tion extended between 0.5 and 15 years with a mean of
4.58 ± 3.36 years. Their body mass index (BMI) ranged be-
tween 19.72 and 44.41 kg/m2 with a mean of 26.19 ± 4.48,
where 11 patients had a normal BMI, 4 were underweight,
18 were overweight, 6 were obese and only 1 patient was mor-
bidly obese. As for Group B 40 apparently healthy age –
matched females served as the control group. Their age ranged
between 18 and 47 with a mean of 28.45 ± 7.53 years. Their
BMI ranged between 20.8 and 42.6 kg/m2 with a mean of
26.38 ± 4.01, where 15 of them had a normal BMI, 19 were
overweight, 5 were obese and only 1 volunteer was morbidly
obese.
The clinical characteristics of Group (A) patients are listed
in Table 1, while the laboratory characteristics of both groups
are shown in Table 2.
Table 2 Laboratory characteristics of studied Groups: SLE patients (Group A) and control (Group B).
Parameter Group (A): patients Group (B): controls p Value
Mean ± SD Range Mean ± SD Range
Hb (g/dl) 10.7 ± 2.02 5.9–13.4 12.45 ± 0.83 10.5–13.8 0.000*
TLC (·103/mm3) 6.2 ± 2.36 1.6–11.7 6.95 ± 1.98 4.1–11.1 NS
Platelets (·103/mm3) 256.8 ± 88.62 75–421 263.15 ± 53.07 172–371 NS
ESR (mm/1sth) 52.5 ± 24.78 10–120 14.55 ± 6.04 5–26 0.000*
ALT (U/L) 23.52 ± 12 7–73 25.45 ± 12.55 5 –65 NS
AST (U/L) 26.18 ± 11.98 9–69 27.43 ± 15.36 11–80 NS
Urea (mg/dl) 36.08 ± 16.35 13–90 31.8 ± 7.13 13–43 NS
Creatinine (mg/dl) 0.79 ± 0.37 0.4–2.4 0.73 ± 0.2 0.5–1.2 NS
TC (mg/dl) 259.08 ± 68.75 143–376 159 ± 38.15 73–240 0.000*
TG (mg/dl) 228.23 ± 83.27 96–428 127.03 ± 36.02 76–213 0.000*
HDL (mg/dl) 41.88 ± 6.92 31–60 59.5 ± 10.5 39–78 0.000*
LDL (mg/dl) 171.53 ± 54.12 81–265 74.8 ± 24.77 19–120 0.000*
C3 (mg/dl) 92.28 ± 52.54 13.5–185 135.49 ± 25.42 90.3–185 0.000
*
C4 (mg/dl) 16.73 ± 12.74 2.5–43 28.52 ± 8.28 12.1–42 0.000
*
Hb: hemoglobin, TLC: total leucocytic count, ESR: erythrocyte sedimentation rate, ALT: alanine transaminase, AST: aspartate transaminase,
TC: total cholesterol, TG: triglycerides, HDL: high density lipoprotein, LDL: low density lipoprotein, C: complement.
* Signiﬁcant (p< 0.05) NS: nonsigniﬁcant.
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Figure 1 Comparison between PON1 activity in Group (A) SLE
patients and Group (B) Controls.
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Figure 2 Comparison between anti-Apo A-I antibody (Anti-
Apo A-I) levels in Group (A) SLE patients and Group (B)
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Figure 3 Correlation between the PON1 activity and anti-Apo –
A-I levels among Group (A) patients.
210 E.M. Elserougy et al.Regarding drug consumption among Group (A) patients,
all of them (100%) were on corticosteroids, and in addition
31 (77.5%) were receiving antimalarials, 22 (55%) were on aza-
thioprine, and only 9 patients (22.5%) were on cyclophospha-
mide therapy.
The serum paraoxonase 1 (PON1) activity levels were
126.2 ± 7.79 U/ml (range 99.8–138.1 U/ml) in Group (B) con-
trols, as compared to 95.92 ± 8.11 U/ml (range 78.1–108.4 U/
ml) in group (A) SLE patients, which was signiﬁcantly lower
(p= 0.001) (Fig. 1).
The mean plasma anti-Apo A-I antibody level (Anti-Apo
A-I) in Group (B) controls was 24.57 ± 6.51 U/L (range
17.5–39.6 U/L), as compared to 33.5 ± 6.92 U/L (range
20.1–54.3 U/L) in Group (A) SLE patients, which was signiﬁ-
cantly higher (p= 0.000) (Fig. 2).
Additionally, a signiﬁcant negative correlation was estab-
lished between serum PON1 activity level and plasma anti-
ApoA-I level among Group (A) SLE patients (r= 0.506,
p= 0.001) (Fig. 3).
The mean disease activity index (SLEDAI) scores in group
(A) SLE patients was 7.9 ± 6.67 (range 0–28), which showed a
signiﬁcant negative correlation with the PON1 activity
(r= 0.402, p= 0.01) (Fig. 4), and a signiﬁcant positivecorrelation with the anti-Apo A-I antibody levels (r= 0.602,
p= 0.0001) (Fig. 5).
The damage index among Group (A) SLE patients as ex-
pressed by the SL ICC/ACR scores was 0.95 ± 0.96 (range
0–3), where 29 patients showed no damage. Patients with
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Figure 4 Correlation between PON1 activity and SLEDAI
scores in group (A) SLE patients.
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Figure 5 Correlation between anti-Apo A-I levels and SLEDAI
scores in group (A) SLE patients.
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tween SLICC/ACR scores and PON1 activity (r= 0.715,
p= 0.013) and on the contrary a signiﬁcant positive correla-
tion was elicited with the anti-Apo A-I antibody levels
(r= 0.763, p= 0.006) (Fig. 6).Figure 6 Correlation between both PON1 activity and anti-ApoThe correlation between the demographic characteristics of
group (A) SLE patients (age, disease duration or BMI) did not
show any signiﬁcance.
As for the clinical characteristics, the PON1 activity levels
showed a statistically signiﬁcant difference between the pres-
ence and absence of constitutional symptoms (p= 0.038),
and CNS manifestations (p= 0.03).
Regarding laboratory investigations, the anti-Apo A-I lev-
els showed a signiﬁcant negative correlation with serum levels
of both C3 (r= 0.316, p= 0.047) and C4 (r= 0.416,
p= 0.008).
The therapeutic protocols did not show any signiﬁcant cor-
relation with the PON1 activity nor anti-Apo A-I levels,
regarding drugs, duration of treatment, nor doses.
4. Discussion
Systemic lupus erythematosus is a chronic inﬂammatory disor-
der characterized by the production of autoantibodies against
a variety of self antigens, generation of immune complexes,
and activation of the complement system [16].
Patients with SLE have a signiﬁcantly increased risk of
CVD morbidity, and mortality, particularly related to prema-
ture atherosclerosis [17].
Epidemiological studies have consistently shown that
plasma HDL was inversely correlated with the incidence
of CVD in the general population. This relationship is
actually quite complex and involves not only the quantity,
but also the quality of HDL. The importance of HDL as
a protective molecule against atherogenesis could be partly
explained by its constituents, mainly Apo A-I and PON1
[18,19].
Paraoxonase 1 is an enzyme synthesized in the liver and is
bound to HDL particles in blood. PON1 appears to contribute
to the antioxidant and anti-atherosclerotic capabilities of HDL
[10]. However, the exact mechanism of PON1’s protective
action and its endogenous substrate remain elusive [20].
The objective of the present study was to assess the two no-
vel risk factors of atherosclerosis in SLE patients; PON1 activ-
ity, anti-Apo A-I antibody levels, to ﬁnd any possibleA-I antibody levels with the SLICC scores in SLE patients.
212 E.M. Elserougy et al.correlation between both of them, and to demonstrate their
relations to disease activity as well as disease related damage.
Forty adult SLE premenopausal female patients diagnosed
according to the ACR revised criteria of SLE and 40 appar-
ently healthy age and culture matched female controls were in-
cluded in this study.
Our study revealed statistically signiﬁcant lower PON1
activity in SLE patients compared to healthy controls. Thus,
our patients are prone to atherosclerosis and its complications.
There is an increasing epidemiological evidence that the PON1
protects against the development of atherosclerosis and is an
independent risk factor for CVD [21]. Our ﬁndings agree with
those of another study which showed that a decreased PON1
activity was associated with clinical atherothrombotic compli-
cations [22]. Furthermore, the atheroprotective function of the
PON1 has also been demonstrated in PON1 knock-out mice,
which exhibited an accelerated atherosclerosis in contrast to
human PON1 transgenic mice where the lesion size was
decreased [23].
The decreased PON1 activity in our patients may be a
cause, or a consequence of SLE. This issue remains unclear.
As a cause, Tripi et al. [24] concluded that a low PON1 activity
is independently associated with SLE and certain PON1 poly-
morphisms are associated with lupus nephritis [24]. On the
contrary, a reduced PON1 activity could be a consequence
of inﬂammation as inﬂammation and proinﬂammatory cyto-
kines diminish the PON1 activity. In addition, inhibition of
PON1 may be a consequence of SLE associated oxidative
stress [11,24].
Assessment of the PON1 activity in SLE patients showed
conﬂicting results. Most studies reported a decline in the
PON1 activity [11,25,26]. These investigators assessed the
PON1 activity by paraoxon as a substrate in their assay. On
the other hand, Tripi et al. [24] as well as Kiss et al. [22] used
both phenyl acetate and paraoxon as substrates in their assay
in the same SLE patients, and both studies found a signiﬁcant
decline in the PON 1 activity when assessed by paraoxon
[22,24]. However, on assessment of the PON 1 activity by phe-
nyl acetate Tripi et al. [24] reported a signiﬁcant increase in the
PON1 activity in their patients [24], whereas, Kiss et al. [22] did
not ﬁnd any signiﬁcant change in the PON1 activity [22]. In
our study we used phenyl acetate as a substrate for assessment
of the PON 1 activity.
These contrasting results of the PON1 activity levels in SLE
may be attributed to the fact that the PON1 activity differs
greatly among ethnic groups. Inter-individual variation in the
PON1 activity is under a strong genetic inﬂuence [27]. In addi-
tion, factors including gender, lifestyle factors, and pharmaco-
logical agents can also modulate the PON1 activity [28]. On the
other hand, the difference in the results of PON1 activity levels
in the same patients of Tripi et al. [24] and Kiss et al. [22] may
be attributed to genotype variation and polymorphism [22,24].
Polymorphisms can inﬂuence enzyme activity i.e. the same
polymorphism can generate opposite effects on the PON1
activity depending on the type of substrate used [28].
Using phenyl acetate in our study as a substrate minimizes
the role of genotype variation as suggested by Precourt et al.
[28]. It is considered as the best substrate in reﬂecting the anti-
oxidant activity of PON1 [29]. The difference between our re-
sults and those of Tripi et al. [24] and Kiss et al. [22] who used
phenyl acetate also in their studies appears to be due to the
exclusion of the individuals taking statins from our study.The use of statins has in general been associated with an
increase in the PON1 serum activity measures [30].
Regarding the correlation between PON1 activity and SLE
disease activity assessed by SLEDAI scores in our study,
PON1 activity showed statistically signiﬁcant negative correla-
tion with such scores. In concordance with our results, Batuca
et al. [11] found a signiﬁcant negative correlation between
PON1 activity and British Isles Lupus Assessment Group (BI-
LAG-2004) disease activity index [11].
It has been reported that SLE activity is associated with
deterioration of the antioxidant status [11]. Increased oxidative
stress inactivates PON1, and a decline in the PON1 activity in
turn augments oxidative stress. Therefore, the trio of disease
activity, oxidative stress, and PON1 activity forms a vicious
circle and this explains the negative correlation between
PON1 activity and SLEDAI [30,31].
In contrast to our results Kiss et al. [22] found no correla-
tion between PON1 activity and SLEDAI, which may be
attributed to the relatively lower SLEDAI scores of the pa-
tients included in their study (2 versus 7.9) [22].
There was a statistically signiﬁcant negative correlation be-
tween SLICC/ACR damage index scores and the PON1 activ-
ity in our study. Our data are consistent with a previous report
[11].
The reported oxidative stress in SLE can damage macro-
molecules, including DNA and can exacerbate inﬂammation
leading to tissue damage [32]. This may be an explanation
for the statistically signiﬁcant negative correlation between
SLICC/ACR scores and the PON1 activity.
In this study, statistically signiﬁcant differences were ob-
tained between the PON1 levels in the presence and absence
of constitutional and CNS manifestations only. Otherwise,
no signiﬁcant differences were present between the PON1 lev-
els in the presence and absence of other clinical manifestations.
To our knowledge, this is the ﬁrst study to address this rela-
tionship between PON1 activity levels and constitutional as
well as CNS manifestations in SLE. On the other hand, Tripi
et al. [24] found decreased (though non-signiﬁcant) PON1
activity levels in lupus nephritis patients compared to SLE pa-
tients without lupus nephritis [24].
Apolipoprotein A-I is another important component of
HDL and it has cardioprotective effects. It plays a major role
in cholesterol homeostasis and it exerts both anti-inﬂamma-
tory and antioxidant properties [8]. Apo A-I exerts its anti-oxi-
dant properties by stabilizing the PON1 enzyme [9]. Deﬁciency
of Apo A-I could lead to deranged processes of immunity [33].
Autoantibodies directed to Apo A-I molecules may inhibit
their normal functions [34]. These antibodies may be present
in general population but in low titers and they may be related
to the vascular and immune aging processes [26].
In this study, there was a statistically signiﬁcant higher anti-
ApoA-I antibody level in SLE patients as compared to controls,
as previously reported in many researches [11,26,33,35,36].
However, there is paucity of information about its exact patho-
physiological role [34]. Anti-Apo A-I antibody production may
be explained by the fact that autoantibody production against
multiple self antigens is considered as a hallmark of SLE [37].
Oxidative stress reported in SLE may be a possible mechanism
for increased autoantibody production. In autoimmune dis-
eases, oxidative stress is the major event causing structural
modiﬁcations of proteins with consequent appearance of neo-
epitopes which can become targets of autoimmune reactions,
Study of anti-apolipoprotein A-I antibodies and paraoxonase 1 activity in systemic lupus erythematosus patients 213thus sustaining the inﬂammatory mechanisms involved in endo-
thelial dysfunction and plaque development [38].
These autoantibodies may lead to Apo A-I dysfunction.
Apo A-I normally contributes in the removal of damaged
and apoptotic endothelial cells. Thus, anti-Apo A-I antibodies
that inhibit these normal functions could predispose to auto-
immunity and may play a role in the pathogenesis of SLE.
Even if these antibodies arise later, in the development of the
disease, and even if the disease is already established, these
antibodies may promote a vicious cycle perpetuating the path-
ological process underlying the disease [33,34].
Apolipoprotein A-I antibodies can affect atherosclerosis
and thrombosis independent of autoimmunity [34]. It could
represent an emerging CVD risk factor and an independent
predictor of major CVD events [39]. The presence of these
antibodies in our patients might have exposed them to acceler-
ated atherosclerosis as they lose their atheroprotection medi-
ated by Apo A-I. These antibodies can also affect the
normal atheroprotective function of HDL, and the formed
dysfunctional HDLs are proinﬂammatory [34].
Our study revealed statistically signiﬁcant lower C3 and C4
levels in SLE patients compared to healthy controls. However,
the mean values of C3 and C4 in the SLE patients and controls
were within the normal range. Thus, there may be a mild de-
gree of complement activation.
A negative correlation was obtained between anti-Apo A-I
antibody with C3 and C4 levels. Circulating immune com-
plexes (antigen–antibody interaction) have been correlated
with complement activation and autoantibody proﬁles in
SLE [40]. This may be a potential explanation for the activa-
tion and consumption of C3 and C4 associated with the in-
crease in production of autoantibodies against Apo A-I in
our patients.
There was a signiﬁcant positive correlation between anti-
Apo A-I antibody and SLE disease activity was assessed by
SLEDAI scores in our patients. In SLE, levels of certain anti-
bodies such as anti-dsDNA frequently correlate with the dis-
ease activity [36].
Similarly, a signiﬁcant positive correlation was reported be-
tween anti-Apo A-I antibody levels and SLE disease activity
assessed by other different scoring systems such as BILAG
[11,26], and the European Consensus Lupus Activity Measure-
ment (ECLAM) [33].
Furthermore, O’Neill et al. [36] assessed disease activity by
BILAG over a 2-year period. They reported that levels of anti-
Apo A-I antibody were signiﬁcantly higher in patients with a
history of persistently high disease activity than in those with
persistently quiescent disease [36].
In contrast to our results, Shoenfeld et al. [33] did not re-
port any correlation between anti-Apo A-I antibody levels
and SLEDAI scores among Italian patients [33].
Our data showed a statistically signiﬁcant positive correla-
tion between SLICC/ACR scores and anti-Apo A-I antibody
levels, as conﬁrmed by previous study [11]. This can be ex-
plained by the formation of antibody – antigen complexes that
can attach to tissues, ﬁx complement, and cause its damage
[34].
Compared to controls, our patients have dyslipidemia in
the form of reduced levels of HDL and elevated levels of
TC, TG, and LDL, which appears to be related to corticoste-
roid therapy in our patients. This pattern of dyslipidemia is
associated with adverse CVD risk in the general population[41,42]. Two different patterns of dyslipidemia have been de-
scribed in SLE. One pattern, referred to as ‘‘active SLE
proﬁle’’, is characterized by decreased HDL, and elevated
LDL and TG. The second pattern resembles the ﬁrst one but
with increased levels of TC, and is seen with the high dose of
steroid therapy [43].
Based on these studies, our patients appear to be in a pro-
atherogenic state. Traditional risk factors involved in the path-
ogenesis of atherosclerosis in our patients include
dyslipidemia, corticosteroid administration and hypertension.
SLE-related risk factors in our patients include: immune sys-
tem involvement (anti-Apo A-I antibody production), and oxi-
dative stress (reduced PON1 activity) [18].
Increasing evidence has highlighted the role of oxidative
stress in both SLE as well as atherosclerotic CVD. Although,
the molecular bases of the interaction between increased oxida-
tive stress, SLE and atherosclerosis remain unclear [31,44], our
study may provide a plausible explanation for these clues.
Paraoxonase 1 (PON1) physiologically plays an important
role in decreasing oxidative stress and atherosclerosis risk, as
it accounts for most of the capacity of HDL to prevent oxida-
tion of LDL [21]. So, the reduced PON1 activity in our pa-
tients might have a deleterious effect on the protective
function of HDL. SLE is associated with intense antibody pro-
duction and a possible mechanism for the reduced antioxidant
PON1 activity may be the autoantibody production against
Apo A-I present in our patients [45]. The statistically signiﬁ-
cant negative correlation between PON1 and anti-Apo A-I
antibody in the present study together with other research
groups highlighted this concept [11,26].
Our results suggest the presence of a vicious circuit between
PON1 activity and anti-Apo A-I antibody. Reduced PON1
activity affects HDL functions and this enhances the oxidative
stress. Oxidative stress leads to the formation of new antigens
which in turn enhances the humoral response leading to the
production of autoantibodies including anti-Apo A-I antibod-
ies. Anti-Apo A-I antibodies target PON1 reducing its activity
[21,45]. Such a vicious circuit with its components maintains
oxidative stress and subsequent SLE-related pro-atherogenic
state.
Diminished HDL levels have been recognized as an inde-
pendent risk factor for CVD. However, there is an increasing
evidence that HDL quality may be as important as its quan-
tity. The concept of ‘‘dysfunctional HDL’’ or ‘‘proinﬂamma-
tory HDL’’ is an emerging issue. Dysfunctional HDL
converts a positive force protecting arteries to a negative
one, enhancing atherogenesis [46]. Among the factors that con-
vert HDL into ‘‘dysfunctional HDL’’ is the decrease of the ma-
jor antioxidant enzyme PON1. Another major structural and
functional component of HDL is Apo A-I. Autoantibodies
against Apo A-I may lead to Apo A-I dysfunction with sec-
ondary HDL dysfunction [34,47].
High density lipoprotein (HDL) may be affected in our
SLE patients in the same manner. The two main components
that account for most of the protective functions of HDL
are affected. PON1 activity is diminished and Apo A-I are tar-
geted by an anti-Apo A-I antibodies. So, our patients appear
to have dysfunctional HDL which represents another pro-ath-
erogenic factor in our SLE patients [47].
Finally, over the next few years, the two SLE related risk
factors of atherosclerosis in this study anti-Apo A-I antibodies
and/or the PON1 activity may be recommended as a routine
214 E.M. Elserougy et al.strategy to stratify SLE patients for risk of accelerated
atherosclerosis.
In conclusion, there is a decreased PON1 activity and for-
mation of anti-Apo A-I antibodies in patients with SLE. Both
of them may be involved in the proatherogenic state noticed in
these patients. SLE-disease activity assessed by SLEDAI and
SLE disease related organ damage assessed by SLICC/ACR
damage index are negatively correlated with the PON1 activity
and positively correlated with anti-Apo A-I antibodies.
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None.
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